Agilent Technologies (A) Raised to Buy at ValuEngine
ValuEngine upgraded shares of Agilent Technologies (NYSE:A) from a hold rating to a buy rating in a research report released on Thursday morning.
Other equities analysts have also issued reports about the company. Morgan Stanley restated an overweight rating on shares of Agilent Technologies in a research report on Tuesday, November 14th. Deutsche Bank set a $75.00 price target on Agilent Technologies and gave the stock a buy rating in a research report on Tuesday, November 21st. Cowen restated a hold rating and set a $70.00 price target on shares of Agilent Technologies in a research report on Wednesday, November 22nd. Barclays raised their price target on Agilent Technologies from $67.00 to $71.00 and gave the stock an overweight rating in a research report on Tuesday, November 21st. Finally, JPMorgan Chase & Co. raised their price target on Agilent Technologies to $75.00 and gave the stock an overweight rating in a research report on Tuesday, November 21st. Four equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The stock currently has a consensus rating of Buy and an average target price of $70.98.
Agilent Technologies (A) opened at $67.51 on Thursday. The company has a current ratio of 3.23, a quick ratio of 2.78 and a debt-to-equity ratio of 0.40. Agilent Technologies has a 1 year low of $50.86 and a 1 year high of $75.00. The stock has a market capitalization of $21,790.00, a P/E ratio of 30.14, a P/E/G ratio of 2.26 and a beta of 1.30.
In other news, VP Mark Doak sold 4,154 shares of the firm’s stock in a transaction that occurred on Tuesday, December 5th. The stock was sold at an average price of $67.00, for a total value of $278,318.00. Following the completion of the transaction, the vice president now owns 68,270 shares in the company, valued at approximately $4,574,090. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Michael R. Mcmullen sold 43,703 shares of the firm’s stock in a transaction that occurred on Friday, January 5th. The shares were sold at an average price of $70.00, for a total value of $3,059,210.00. Following the completion of the transaction, the chief executive officer now owns 302,837 shares of the company’s stock, valued at approximately $21,198,590. The disclosure for this sale can be found here. Over the last quarter, insiders sold 107,124 shares of company stock worth $7,618,959.
Several institutional investors and hedge funds have recently added to or reduced their stakes in A. Nationwide Fund Advisors lifted its stake in shares of Agilent Technologies by 132.5% in the 3rd quarter. Nationwide Fund Advisors now owns 575,282 shares of the medical research company’s stock valued at $36,933,000 after purchasing an additional 327,822 shares during the period. Pictet Asset Management Ltd. lifted its stake in shares of Agilent Technologies by 11.7% in the 3rd quarter. Pictet Asset Management Ltd. now owns 723,113 shares of the medical research company’s stock valued at $46,424,000 after purchasing an additional 75,905 shares during the period. Crossmark Global Holdings Inc. purchased a new position in shares of Agilent Technologies in the 3rd quarter valued at approximately $2,597,000. Canada Pension Plan Investment Board lifted its stake in shares of Agilent Technologies by 4.4% in the 3rd quarter. Canada Pension Plan Investment Board now owns 969,719 shares of the medical research company’s stock valued at $62,256,000 after purchasing an additional 41,000 shares during the period. Finally, Dupont Capital Management Corp purchased a new position in shares of Agilent Technologies in the 3rd quarter valued at approximately $101,000.
TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2018/03/05/agilent-technologies-a-raised-to-buy-at-valuengine.html.
About Agilent Technologies
Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.